KB501

KB501 is an investigational **TNF-α targeted therapy** attributed to **Krystal Biotech**. Publicly accessible secondary pipeline databases describe it as a drug candidate directed against **tumor necrosis factor alpha** for **skin and musculoskeletal diseases**, while another source describes **KB-501** as a **preclinical gene therapy** being developed for **atopic dermatitis**. Because Krystal Biotech's current public pipeline pages do not clearly list KB501, the exact modality, formulation, and development context remain incompletely verified from primary company materials. The most defensible interpretation is that KB501 is an early-stage Krystal Biotech program intended to inhibit TNF-α signaling in inflammatory disease, but key details should be treated as provisional.